These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 16306032)
1. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. Kappelhoff BS; Huitema AD; van Leth F; Robinson PA; MacGregor TR; Lange JM; Beijnen JH; HIV Clin Trials; 2005; 6(5):254-61. PubMed ID: 16306032 [TBL] [Abstract][Full Text] [Related]
2. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Kappelhoff BS; van Leth F; MacGregor TR; Lange J; Beijnen JH; Huitema AD; Antivir Ther; 2005; 10(1):145-55. PubMed ID: 15751772 [TBL] [Abstract][Full Text] [Related]
3. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Wit FW; Lange JM; Danner SA; Foudraine NA; Kwakkelstein MO; Reiss P; Beijnen JH; Hoetelmans RM AIDS; 2000 May; 14(8):F77-82. PubMed ID: 10853971 [TBL] [Abstract][Full Text] [Related]
4. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES). Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030 [TBL] [Abstract][Full Text] [Related]
5. Steady-state pharmacokinetics of lamivudine once-daily versus twice-daily dosing in Chinese HIV-infected patients. Ye M; Wang L; Fu Q; Zhu Z; Li P; Li T HIV Clin Trials; 2010; 11(4):230-7. PubMed ID: 20974578 [TBL] [Abstract][Full Text] [Related]
6. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Kappelhoff BS; van Leth F; Robinson PA; MacGregor TR; Baraldi E; Montella F; Uip DE; Thompson MA; Russell DB; Lange JM; Beijnen JH; Huitema AD; Antivir Ther; 2005; 10(4):489-98. PubMed ID: 16038474 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. Leth FV; Kappelhoff BS; Johnson D; Losso MH; Boron-Kaczmarska A; Saag MS; Livrozet JM; Hall DB; Leith J; Huitema AD; Wit FW; Beijnen JH; Lange JM; AIDS Res Hum Retroviruses; 2006 Mar; 22(3):232-9. PubMed ID: 16545009 [TBL] [Abstract][Full Text] [Related]
8. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Siegfried NL; Van Deventer PJ; Mahomed FA; Rutherford GW Cochrane Database Syst Rev; 2006 Apr; 2006(2):CD004535. PubMed ID: 16625606 [TBL] [Abstract][Full Text] [Related]
9. Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study. Parienti JJ; Massari V; Reliquet V; Chaillot F; Le Moal G; Arvieux C; Vabret A; Verdon R; AIDS; 2007 Oct; 21(16):2217-22. PubMed ID: 18090049 [TBL] [Abstract][Full Text] [Related]
10. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM; Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. Gathe J; Andrade-Villanueva J; Santiago S; Horban A; Nelson M; Cahn P; Bogner J; Spencer D; Podzamczer D; Yong CL; Nguyen T; Zhang W; Drulak M; Quinson AM Antivir Ther; 2011; 16(5):759-69. PubMed ID: 21817198 [TBL] [Abstract][Full Text] [Related]
12. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Ellis JC; L'homme RF; Ewings FM; Mulenga V; Bell F; Chileshe R; Molyneux E; Abernethy J; van Oosterhout JJ; Chintu C; Walker AS; Gibb DM; Burger DM Antivir Ther; 2007; 12(2):253-60. PubMed ID: 17503667 [TBL] [Abstract][Full Text] [Related]
14. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. Cooper CL; van Heeswijk RP HIV Med; 2007 Jan; 8(1):1-7. PubMed ID: 17305925 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. Musiime V; Kendall L; Bakeera-Kitaka S; Snowden WB; Odongo F; Thomason M; Musoke P; Adkison K; Burger D; Mugyenyi P; Kekitiinwa A; Gibb DM; Walker AS; Antivir Ther; 2010; 15(8):1115-24. PubMed ID: 21149918 [TBL] [Abstract][Full Text] [Related]
16. Once-daily dosing of nevirapine in HAART. Clotet B J Antimicrob Chemother; 2008 Jan; 61(1):13-6. PubMed ID: 18006524 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. Hosseinipour MC; Corbett AH; Kanyama C; Mshali I; Phakati S; Rezk NL; van der Horst C; Kashuba AD AIDS; 2007 Jan; 21(1):59-64. PubMed ID: 17148968 [TBL] [Abstract][Full Text] [Related]
18. Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets. Poerksen G; Pollock L; Moons P; Chesshyre E; Burger D; Khoo S; Molyneux E Antivir Ther; 2010; 15(3):343-50. PubMed ID: 20516554 [TBL] [Abstract][Full Text] [Related]
19. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107 [TBL] [Abstract][Full Text] [Related]